Recent Development and Perspective of Thrombolytic Drugs

Arterial thrombosis is the underlying cause of a wide variety of cerebro-cardiovascular diseases.All the currently used thrombolytic agents are very efficient in restoring the blood flow.The recent development in thrombolytic drugs,including the third-generation thromblytic agents and natural thromblytic agents,is presented in this article.The thrombolytic mechanism,adverse reaction and the clinical application of these drugs are especially introduced.Most of the third-generation thromblytic agents are variants of tissue type plasmino-gen activator,such as reteplase,monteplase,tenecteplase and lanoteplase.All of them and some natural thromblytic agents including staphylokinase,lumbrokinase and hirudin are plasminogen activators,which can convert plasminogen into plasmin and thus degrade fibrin.They have showed considerable potential with higher potency,specific thrombolytic activity,fibrin selectivity and longer half-life time,but all these agents suffer from a number of inadequacies including resistance to reperfusion,occurrence of coronary reocclusion and bleeding complications.The thrombolytic mechanism of nattokinase and fibrinolytic enzyme in douchi are specific,and they won't cause bleeding complications.The further develoment of thrombolytic agents is how they can get safer and cheaper.